Previous close | 2.8200 |
Open | 2.2900 |
Bid | 1.9100 |
Ask | 2.1700 |
Strike | 125.00 |
Expiry date | 2024-05-03 |
Day's range | 1.6000 - 2.5300 |
Contract range | N/A |
Volume | |
Open interest | 204 |
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.